4//SEC Filing
Gleeson Michael 4
Accession 0001487371-21-000072
CIK 0001487371other
Filed
Feb 21, 7:00 PM ET
Accepted
Feb 22, 7:03 PM ET
Size
10.5 KB
Accession
0001487371-21-000072
Insider Transaction Report
Form 4
Gleeson Michael
SVP, Sales
Transactions
- Sale
Common Stock
2021-02-19$21.80/sh−2,340$51,012→ 414,388 total - Award
Market Stock Units
2021-02-18+6,250→ 6,250 totalExercise: $0.00→ Common Stock (6,250 underlying) - Award
Common Stock
2021-02-18+18,750→ 416,728 total
Holdings
- 30,069(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2020 Equity Incentive Plan. The restricted stock units vest 25% on February 18, 2022 and the remaining shares subject to such award vest in 12 equal quarterly installments thereafter.
- [F2]The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units.
- [F3]Mr. Gleeson is the trustee of the Michael William Gleeson 2012 Irrevocable Trust and has voting and dispositive power with respect to these shares. Mr. Gleeson disclaims beneficial ownership except to the extent of his pecuniary interest therein.
- [F4]Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index.
- [F5]The MSUs vest in three equal installments, on each of December 31, 2021, December 31, 2022, and December 31, 2023; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index.
Documents
Issuer
GenMark Diagnostics, Inc.
CIK 0001487371
Entity typeother
Related Parties
1- filerCIK 0001543884
Filing Metadata
- Form type
- 4
- Filed
- Feb 21, 7:00 PM ET
- Accepted
- Feb 22, 7:03 PM ET
- Size
- 10.5 KB